AstraZeneca and GSK, the U.K.'s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.
In this article
Pharma giants AstraZeneca
and GSK
, the U.K.’s second and ninth most valuable companies, both saw first-quarter profits beat expectations early Wednesday.
AstraZeneca’s core earnings per share came in at $2.58, while analysts polled by FactSet had expected $2.53. GSK’s core EPS was £0.47 ($0.63) versus the expected £0.43, as per FactSet.
Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer
Il gruppo ha realizzato un incremento del fatturato del 12%, a quota 14,5 miliardi di dollari, e del 10% dell’utile per azione a…
Ian King takes a look at the clouds gathering over the pharmaceuticals sector, hitherto one of the U.K.'s most successful…
The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a £1 billion facility in…
Drug companies increasingly frustrated with the Government over surging NHS clawbacks
